AI leaders push Congress for DNA safeguards

Jakob Uszkoreit helped build the transformer architecture — the “T” in ChatGPT — that fueled the generative AI boom. Now, he’s pivoting to biology, leading a startup called Inceptive Nucleics. The company aims to create biological foundation models, a concept borrowed from AI, but applied to sequence-based medicines like mRNA, antisense drugs, and RNA interference therapies. This shift reflects a growing trend: tech leaders exploring biotech’s next frontier.

From AI to biology: A new kind of model

Uszkoreit’s work on transformers transformed natural language processing by letting computers understand and generate text. Now, his team is adapting similar principles to biological sequences. “We’re building models that can predict how RNA or DNA folds, how proteins interact, or how a drug might bind to a target,” said one insider. These models could streamline drug development, reducing the time and cost of creating treatments.

Inceptive Nucleics’ approach mirrors AI’s use of large datasets to train models. Instead of text, the startup is analyzing genetic code, protein structures, and chemical interactions. This could help design better therapies for diseases like cancer or rare genetic disorders. “The goal is to make drug development more predictable,” said a company representative.

Related: Trump administration strips protections for top NIH officials

The startup is not alone. Other AI firms are experimenting with biotech applications, from protein engineering to personalized medicine. But Uszkoreit’s background in AI gives Inceptive Nucleics a unique edge. “He understands how to scale models and apply them to real-world problems,” noted a biotech analyst.

Challenges ahead

Despite the promise, the path is fraught with obstacles. Unlike AI, where models can be tested quickly, biological systems are complex and unpredictable. “You can’t just run a simulation and know if a drug will work in humans,” said one researcher. Clinical trials remain a critical hurdle for any new therapy.

Inceptive Nucleics is also handling regulatory scrutiny. The FDA and other agencies are cautious about new approaches, especially those involving genetic material. “They want to see proof of safety and efficacy before approving anything,” said a healthcare policy expert. This could slow the company’s progress, but it’s a risk many biotech startups take.

Related: 17 Advanced Tips to Improve Your Healthy News

Funding is another concern. While AI startups often attract billions in investment, biotech ventures face steeper challenges. Inceptive Nucleics has raised some capital, but scaling up will require more. “They’ll need to show early results to convince investors,” said a venture capitalist.

A broader shift in tech and medicine

Uszkoreit’s move reflects a larger trend: tech leaders expanding into biotech. Companies like Google, Microsoft, and DeepMind have already invested heavily in life sciences. This cross-pollination of ideas is reshaping both industries. “AI is accelerating drug discovery, but biology is the next big frontier,” said a Silicon Valley executive.

However, this fusion raises ethical questions. Who controls the data? How are models trained? “There’s a risk of overhyping results,” warned a bioethicist. Transparency and accountability will be key as these technologies evolve.

Related: 47 Complete Tips to Improve Your Health Insurance

For now, Inceptive Nucleics is focused on proving its concept. If successful, it could open new doors for AI-driven biotech. But the journey from lab to market is long, and the stakes are high.

The company’s first tests are underway, but results are not yet public. Investors and scientists are watching closely. “This could be a turning point,” said one observer. “Or it could be another dead end.”